Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.57 |
| ▸ | HTR3A | P46098 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL978037 | 0.87 | LMNA (0.77) | RAB9AKMT2ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL6280297 | 0.82 | KMT2A (0.68) | RAB9AKMT2ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL5979204 | 0.81 | KMT2A (0.49) | RAB9AKMT2ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL7367818 | 0.81 | LMNA (0.68) | RAB9AKMT2ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL25305562 | 0.80 | UGCG (0.59) | RAB9AKMT2ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL9219100 | 0.79 | ADORA3 (0.50) | RAB9AKMT2ANPC1SMN1; SMN2MEN1 | |
| Anthranilamide SCHEMBL6280290 | 0.76 | KMT2A (0.67) | RAB9AKMT2ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL5723065 | 0.76 | RAB9A (1.00) | RAB9AKMT2ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL219813 | 0.75 | LMNA (1.00) | RAB9AKMT2ANPC1SMN1; SMN2MEN1 | |
| SCHEMBL16264729 | 0.75 | CHRNA7 (0.54) | RAB9AKMT2ANPC1SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2022-06-14 | — | — | US | disclosed |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2021-11-04 | — | — | US | disclosed |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | NOVARTIS AG (CH) | 2020-04-09 | — | — | US | disclosed |
| US-20180037957-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2018-02-08 | — | — | US | disclosed |
| EP-2931315-B1 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | NOVARTIS AG (CH) | 2017-11-29 | — | — | EP | disclosed |
| US-9828642-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | NOVARTIS AG (CH) | 2017-11-28 | — | — | US | disclosed |
| US-20160122337-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2016-05-05 | — | — | US | disclosed |
| US-20160122337-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2016-05-05 | — | — | US | disclosed |
| US-20160122337-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2016-05-05 | — | — | US | disclosed |
| EP-2931315-A2 | BIOMARKER PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | Novartis AG (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-20110263591-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER SCHERING PHARMA AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263591-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER SCHERING PHARMA AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-20110263591-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER SCHERING PHARMA AG (DE) | 2011-10-27 | — | — | US | disclosed |
| US-7977485-B2 | 2-heteroaryl carboxamides | BAYER SCHERING PHARMA AKTIENGESELLSHAFT (DE) | 2011-07-12 | — | — | US | disclosed |
| US-7977485-B2 | 2-heteroaryl carboxamides | BAYER SCHERING PHARMA AKTIENGESELLSHAFT (DE) | 2011-07-12 | — | — | US | disclosed |
| US-7977485-B2 | 2-heteroaryl carboxamides | BAYER SCHERING PHARMA AKTIENGESELLSHAFT (DE) | 2011-07-12 | — | — | US | disclosed |
| EP-1515967-B1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2006-11-02 | — | — | EP | disclosed |
| US-20060160877-A1 | 2-Heteroaryl carboxamides | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-20 | — | — | US | disclosed |
| EP-1515967-A1 | 2-HETEROARYL CARBOXAMIDES | Bayer HealthCare AG (DE) | 2005-03-23 | — | — | EP | disclosed |
| WO-2003104227-A1 | 2-HETEROARYL CARBOXAMIDES | BAYER HEALTHCARE AG (DE) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037957-A1 | BIOMARKERS PREDICTIVE OF RESPONSIVENESS TO ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATOR TREATMENT | CHRNA7, CHRNA4, CHRNA5 | RAB9A 1278/4885KMT2A 2943/4885NPC1 2134/4885 |
| US-20160122337-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | RAB9A 3256/4885KMT2A 204/4885NPC1 94/4885 |
| US-20060160877-A1 | 2-Heteroaryl carboxamides | GRIN2A, CNR2, GRIN2C | RAB9A 3256/4885KMT2A 204/4885NPC1 94/4885 |
| US-20200108035-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | RAB9A 494/4885KMT2A 2657/4885NPC1 2627/4885 |
| US-20110263591-A1 | 2-HETEROARYL CARBOXAMIDES | GRIN2A, CNR2, GRIN2C | RAB9A 3256/4885KMT2A 204/4885NPC1 94/4885 |
| US-11359241-B2 | Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment | CHRNA7, CHRNA4, CHRNA5 | RAB9A 1278/4885KMT2A 2943/4885NPC1 2134/4885 |
| US-20210338621-A1 | USE OF NICOTINIC ACETYLCHOLINE RECEPTOR ALPHA 7 ACTIVATORS | CHRNA7, CHRNA5, CHRNA4 | RAB9A 494/4885KMT2A 2657/4885NPC1 2627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.